Matinas BioPharma Holdings, Inc.
MTNB · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $3 | $0 |
| % Growth | -100% | -65.6% | 9,560.6% | – |
| Cost of Goods Sold | $0 | $0 | $17 | $15 |
| Gross Profit | $0 | $1 | -$13 | -$15 |
| % Margin | – | 100% | -423.1% | -44,090.9% |
| R&D Expenses | $11 | $14 | $17 | $15 |
| G&A Expenses | $9 | $10 | $11 | $10 |
| SG&A Expenses | $9 | $10 | $11 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $0 | -$17 | -$15 |
| Operating Expenses | $25 | $25 | $11 | $10 |
| Operating Income | -$25 | -$24 | -$25 | -$25 |
| % Margin | – | -2,168.4% | -771.3% | -74,954.5% |
| Other Income/Exp. Net | $0 | $1 | $4 | $1 |
| Pre-Tax Income | -$24 | -$23 | -$21 | -$23 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$24 | -$23 | -$21 | -$23 |
| % Margin | – | -2,093.2% | -658.6% | -70,554.5% |
| EPS | -4.98 | -5.28 | -3 | -5.04 |
| % Growth | 5.7% | -76% | 40.5% | – |
| EPS Diluted | -4.98 | -5.28 | -3 | -5.04 |
| Weighted Avg Shares Out | 5 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 5 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$19 | -$23 | -$24 | -$24 |
| % Margin | – | -2,082.6% | -760.2% | -74,106.1% |